GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alzamend Neuro ALZN · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.42

+0.71%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Alzamend Neuro

From its filings with the US Securities and Exchange Commission

SEC filings

Alzamend Neuro is based in Atlanta, Georgia and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ALZN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 April 2026, it reported a net loss of $8.8m. At that date it held total assets of $2.1m and shareholders' equity of $733,211.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
15 Jun 2021
Employees
4
Head office
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA, GA, 30326
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. William HorneChairman of the Board, since 2021$50,000
  • Mr. Stephan JackmanChief Executive Officer, Director, since 2018$468,288
  • Mr. Milton AultVice Chairman of the Board, since 2024$25,000
  • Mr. David KatzoffChief Financial Officer$150,000
  • Mr. Henry NisserExecutive Vice President, General Counsel, Director, since 2019$50,000
  • Mr. Kenneth CragunSenior Vice President - Finance$100,000
  • Mr. Mark GustafsonIndependent Director$25,000
  • Dr. Lynne McgrathIndependent Director$25,000
  • Mr. Jeffrey OramIndependent Director$25,000
  • Dr. Andrew WooIndependent Director$25,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Alzamend Neuro Inc has two patented drug candidates AL001 and ALZN002 for Alzheimer's and mental health disorders.
  • The company holds exclusive worldwide licenses for AL001 and ALZN002 from the University of South Florida Research Foundation.
  • Alzamend Neuro Inc employs four full-time staff in Atlanta, Georgia, focusing on clinical-stage biopharmaceutical development.

Weaknesses

  • The company has only four full-time employees, limiting operational capacity.
  • Alzamend Neuro Inc's clinical-stage development requires significant funding for further trials.
  • The firm's reliance on two drug candidates creates dependency on their success.

Opportunities

  • Alzamend Neuro Inc can expand its pipeline with additional therapeutic candidates for mental health disorders.
  • The growing market for Alzheimer's treatments presents a significant opportunity for the company.
  • Collaborations with larger pharmaceutical firms could accelerate AL001 and ALZN002 development.

Threats

  • Competition from established pharmaceutical companies in Alzheimer's and mental health treatments poses a threat.
  • Regulatory hurdles for clinical-stage biopharmaceuticals may delay product approval.
  • The high cost of clinical trials could strain the company's limited financial resources.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.